期刊
EUROPEAN JOURNAL OF CANCER
卷 41, 期 13, 页码 1854-1863出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2005.04.013
关键词
cancer; chemoprevention; coxib; cyclooxygenase; non-steroidal anti-inflammatory drugs; prostaglandins
类别
资金
- Medical Research Council [G116/146] Funding Source: Medline
- MRC [G116/146] Funding Source: UKRI
There is now substantial evidence for a role for cyclooxygenase-2 (COX-2)-mediated prostaglandin (PG) signalling during carcinogenesis in a number of tissues and selective COX-2 inhibitors (coxibs) were considered attractive candidate chemoprevention agents. However, recent concerns over the toxicity of systemic selective COX-2 inhibition and the realisation that COX-1 may also contribute to carcinogenesis have cast some doubt on COX-2 inhibition as a safe and effective chemoprevention strategy. This review will describe the available evidence relating to the known benefits (preventive efficacy in rodent tumorigenesis models and limited human data from small randomised, controlled trials and epidemiological studies) and risks (cardiovascular and renal toxicity) of coxib therapy for cancer chemoprevention. Potential, alternative strategies for inhibition of COX-PG signalling that minimise or avoid systemic selective COX-2 inhibition will also be discussed. (c) 2005 Elsevier Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据